Overall survival in patients with metastatic castration-sensitive prostate cancer treated with apalutamide versus abiraterone acetate: a head-to-head analysis of real-world patients in the USA
Journal of Comparative Effectiveness Research · 09.05.2025
DOI: 10.57264/cer-2025-0023 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Comparative Effectiveness Research, online erschienen am 09.05.2025. Verfasst von Benjamin Lowentritt und 9 weiteren Autor:innen. Beteiligte Einrichtung: Chesapeake Urology, Towson, MD 21204, USA. Hauptthemen laut MEDLINE: Abiraterone Acetate, Thiohydantoins, Prostatic Neoplasms, Castration-Resistant, Androgen Receptor Antagonists. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Aim
Head-to-head studies of survival outcomes associated with different androgen receptor pathway inhibitor (ARPI) treatments for metastatic castration (hormone)-sensitive prostate cancer have not been conducted. The purpose of this study was to compare 24-month overall survival among ARPI-naive patients with metastatic castration-sensitive prostate cancer (mCSPC) who initiated apalutamide or abiraterone acetate. Materials & methods: Linked de-identified clinical and claims healthcare databases were used to compare overall survival between patients with mCSPC initiating apalutamide or abiraterone acetate treated in community-based urology practices in the USA. Overall survival at 24 months post-treatment initiation (primary analyses) was compared between apalutamide and abiraterone acetate initiators using weighted Cox proportional hazards models (exploratory analyses used all available follow-up).
Results
Overall, 1879 and 2073 patients had initiated apalutamide or abiraterone acetate, respectively (both cohorts: weighted mean age 72 years, 62% were white, and 66% had bone metastasis). At 24 months post-index, patients in the apalutamide cohort had a 26% lower risk of mortality compared with those in the abiraterone acetate cohort (hazard ratio: 0.74; 95% confidence interval: 0.59, 0.93; p = 0.010), with the difference maintained when outcomes were evaluated using all available follow-up (hazard ratio: 0.72; 95% confidence interval: 0.59, 0.88; nominal p < 0.001).
Conclusion
In this nationally representative, real-world head-to-head analysis of nearly 4000 ARPI-naive patients with mCSPC, apalutamide was associated with a 26% reduction in the risk of mortality compared with abiraterone acetate by 24 months post-treatment initiation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Chesapeake Urology, Towson, MD 21204, USA.
- Winship Cancer Institute of Emory University, Atlanta, GA 30322, USA.
- Johnson & Johnson, Horsham, PA 19044, USA.
- Analysis Group, Inc., Montréal, QC H3B 0G7, Canada.
- Carolina Urologic Research Center, Myrtle Beach, SC 29572, USA.
Zitieren
APA
Lowentritt, B., Bilen, M. A., Khilfeh, I., Rossi, C., Du, S., Kinkead, F., Diaz, L., Pilon, D., Ellis, L., & Shore, N. D. (2025). Overall survival in patients with metastatic castration-sensitive prostate cancer treated with apalutamide versus abiraterone acetate: a head-to-head analysis of real-world patients in the USA. Journal of Comparative Effectiveness Research. https://doi.org/10.57264/cer-2025-0023
Vancouver
Lowentritt B, Bilen MA, Khilfeh I, Rossi C, Du S, Kinkead F, et al. Overall survival in patients with metastatic castration-sensitive prostate cancer treated with apalutamide versus abiraterone acetate: a head-to-head analysis of real-world patients in the USA. Journal of Comparative Effectiveness Research. 2025. doi:10.57264/cer-2025-0023
BibTeX
@article{Lowentritt2025,
author = {Lowentritt, Benjamin and Bilen, Mehmet A and Khilfeh, Ibrahim and Rossi, Carmine and Du, Shawn and Kinkead, Frederic and Diaz, Lilian and Pilon, Dominic and Ellis, Lorie and Shore, Neal D},
title = {Overall survival in patients with metastatic castration-sensitive prostate cancer treated with apalutamide versus abiraterone acetate: a head-to-head analysis of real-world patients in the USA},
journal = {Journal of Comparative Effectiveness Research},
year = {2025},
doi = {10.57264/cer-2025-0023}
}
EUVIMED